IMV Inc IMVIF

Presentations

[Hideaway]

IMV will be giving AACR presentation on Apr.12th plus the following two around the same time.Hope they prove to be more productive than past presentations.

APRIL 04, 2022 7:05AM EDT

 

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating in the 21st Annual Needham Virtual Annual Healthcare Conference, which will be held April 11-14, and the Wells Fargo Biotech Forum, which will be held April 12-13.

21st Annual Needham Virtual Healthcare Conference 
Format: Presentation and one-on-one investor meetings 
Date: Thursday April 14, 2022 
Time: 12:45 p.m. ET 
Webcast: Click Here

Wells Fargo Biotech Forum 
Format: One-on-one investor meetings 
Date: April 12-13

[Hideaway]

On reflection,it seems odd that there is no mention of the AACR oral presentation slated for April 12th. Does anyone have any info to confirm their AACR attendance? After reading the last NR,they refer only the two upcoming conferences as if they are the only scheduled with no indication of AACR meeting.  

[LR6852]

Here it is: https://www.abstractsonline.com/pp8/#!/10517/presentation/20386

[LR6852]

Abstract is now available online: Background: Maveropepimut-S (MVP-S) is a novel immunotherapeutic that educates a specific CD8 T cell response to the cancer antigen, survivin, to orchestrate immune-mediated elimination of survivin-expressing cancer cells. Specifically, MVP-S is a lipid-in-oil formulation of the DPX delivery platform, incorporating five survivin-specific immunogenic peptides

[Breakthorough]

ORR: 29'4% (CR 11'8%, PR: 17'6%) mOS (Overall Survival): not reached. But "long-term clinical benefit has been observed in several subjects (one patient is still on treatment after 17 months)" Keytruda was approved for this population in may 2017 with: ORR of 21% (better than the 11% of quimio). NO CR's, I guess. mOS: 10'3 months (better than the 7'4 months of

[Biotech010]

I like the fact that patients who lacked benefit from Pembro, are getting better when MVP is added to the mix.  Looking forward to the presentation and the stock on monday!

[Breakthorough]

Following the data published yesterday at IMV's site, there were just 13 evaluable patients, witj 3 SD, 3 PR and 2 CR.. So it gives, as an orientation (though the cohort is very small): DCR: Intention to Treat, 47% (8 out of 17); Evaluable population, 615% (8 out of 13). ORR: ITT, 294% (5 out of 17); EVp, 385% (5 out of 13).

[Breakthorough]

Following the data published yesterday at IMV's site, there were just 13 evaluable patients, with 3 SD, 3 PR and 2 CR.. So it gives, as an orientation (though the cohort is very small): DCR: Intention to Treat, 47% (8 out of 17); Evaluable population, 61,5% (8 out of 13). ORR: ITT, 29,4% (5 out of 17); EVp, 38,5% (5 out of 13).